Indication/action
Drug name
Dosage
Side effects & precautions
Level of evidencea
Grade of recommendationa
OAB/UUI/MUI
To modulate/reduce and/or suppress bladder overactivity and prevent UI
Oxybutynin IR
2.5–5 mg tds
Dry mouth, blurred vision, nausea constipation, tachycardia
1
A
Oxybutynin ER
5–30 mg od
1
A
Oxybutynin TDS
3.9 mg od
1
A
Oxybutynin IV
5 mg od/tds
1
A
Propantheline
15–30 mg tds/qds
2
B
Tolterodine
2 mg bd
1
A
Tolterodine ER
4 mg
1
A
Trospium
20 mg bd/tds
1
A
Solifenacin
5–10 mg od
1
A
Darifenacin
7.5–15 mg od
1
A
Imipramine
10–25 mg bd/tds
Tachycardia
Hypotension
3
C
Mirabegron
25–50 mg od
1
A
OAB (nocturia)
Desmopressin
0.1–0.2 mg od
1
A
Desmopressin IN
20 μg od
1
A
Bladder outflow overactivity
To decrease bladder outflow resistance
Phenoxybenzamine
10–20 mg od
Orthostatic hypotension, dizziness, fatigue, nasal congestion, retrograde ejaculation
2a
B
Prazosin
1 mg od/bd
2a
B
Doxazosin
1–2 mg od/bd
2a
B
Alfuzosin ER
10 mg od
Terazosin
5–10 mg od
Tamsulosin
0.4 mg od
od once daily, bd twice daily, tds three times daily, qds four times daily, IR immediate release, ER extended release, TDS transdermal, IV intravesically, IN intranasally
Related posts:
Aging Brain and Neurological Changes
Physical Activity and Rehabilitation in Elderly
Neuropsychological Aspects of Language in Older Adults
Rehabilitation in Older Patients with Peripheral Arterial Disease
Rehabilitation for Palliative Care and End-of-Life Management
Rehabilitation of Ageing People with Neurological Disorders
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
